Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | OSPREY: PSMA-targeted PET-CT imaging in prostate cancer

Frédéric Pouliot • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Prostate Cancer
OSPREY

Frédéric Pouliot, MD, PhD, FRCSC, Research Center CHU de Quebec, Université Laval, Quebec, Canada, discusses a subanalysis of metastases detection rates by PSMA-targeted PET-CT in patients with prostate cancer from the OSPREY trial (NCT02981368). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Frédéric Pouliot

4:42
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients with prostate cancer
Frédéric Pouliot • 4 Jun 2021
2:45
ARROW: PSMA-targeted radioligand therapy plus enzalutamide in mCRPC
Frédéric Pouliot • 15 Feb 2021
3:13
18F-DCFPyL PET/CT imaging up-stages patients with prostate cancer
Frédéric Pouliot • 15 Feb 2021
1:25
Role of steroids in sustaining castration resistance
Frédéric Pouliot • 13 Feb 2020

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals